Qasim Agha Osama, Berryman Ryan
Department of Internal Medicine, Creighton University School of Medicine, Phoenix, Arizona, USA.
Department of Internal Medicine, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Case Rep Crit Care. 2020 Sep 4;2020:8880143. doi: 10.1155/2020/8880143. eCollection 2020.
Coronavirus 2019 disease (COVID-19) is a viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It emerged in Wuhan, China, in December 2019 and has caused a widespread global pandemic. The symptoms of COVID-19 can vary from mild upper respiratory symptoms to severe pneumonia with hypoxemic respiratory failure. Multiple studies and reports have reported a hypercoagulable state associated with this disease, and various recommendations have emerged to guide the use of anticoagulants for prophylaxis. We are reporting a case of symptomatic acute splenic thrombosis causing splenic infarction in a patient suffering from a severe case of COVID-19 and despite the use of an intermediate dose of low-molecular-weight heparin (LMWH). The patient was treated with full-dose anticoagulation and was eventually discharged home on a direct oral anticoagulant.
2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的病毒性疾病。它于2019年12月在中国武汉出现，并引发了全球大流行。COVID-19的症状从轻度上呼吸道症状到伴有低氧性呼吸衰竭的严重肺炎不等。多项研究和报告报道了与该疾病相关的高凝状态，并出现了各种指导抗凝剂预防使用的建议。我们报告了一例重症COVID-19患者出现症状性急性脾血栓形成并导致脾梗死的病例，尽管使用了中等剂量的低分子量肝素（LMWH）。该患者接受了全剂量抗凝治疗，最终出院时使用直接口服抗凝剂。
